Consensus Kymera Therapeutics, Inc.

Equities

KYMR

US5015751044

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
33.62 ^USD	-3.00%		-5.85%	+32.05%

Apr. 22	Oppenheimer Starts Kymera Therapeutics With Outperform Rating, $53 Price Target	MT
Apr. 08	Kymera Therapeutics, Inc Announces Scientific Presentations At the American Association for Cancer Research 2024 Annual Meeting	CI

Evolution of the average Target Price on Kymera Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b68e669c9.iLsOUGhfupQLI0HpAeVBlQ6e0MG8RtFo2Wvxk0MYDQs.2_B4NCEt4sV7cBOxUbY4ymD3p5KINoRYrQTIyyp9Tyb56lc7HDr1ozxOLg~350a76095f6358a5424c843306b27dc3

Analyst Recommendations on Kymera Therapeutics, Inc.

Oppenheimer Starts Kymera Therapeutics With Outperform Rating, $53 Price Target	Apr. 22	MT
Truist Ups Price Target on Kymera Therapeutics to $54 From $41, Keeps Buy Rating	Mar. 01	MT
Piper Sandler Raises Price Target on Kymera Therapeutics to $56 From $39, Maintains Overweight Rating	Feb. 27	MT
B. Riley Adjusts Kymera Therapeutics' Price Target to $31 From $16, Keeps Neutral Rating	Feb. 23	MT
Wolfe Research Starts Kymera Therapeutics With Peer Perform Rating	Feb. 15	MT
Morgan Stanley Raises Price Target on Kymera Therapeutics to $33 From $24, Keeps Equalweight Rating	Jan. 08	MT
BofA Securities Downgrades Kymera Therapeutics to Neutral From Buy, Price Target is $30	Jan. 03	MT
Morgan Stanley Adjusts Kymera Therapeutics' Price Target to $24 From $37, Maintains Equalweight Rating	Nov. 13	MT
HC Wainwright Adjusts Price Target on Kymera Therapeutics to $30 From $85, Maintains Buy Rating	Nov. 03	MT
B. Riley Lowers Kymera Therapeutics' PT to $16 From $37 Following Disappointing Oncology Updates, Keeps Neutral Rating	Nov. 03	MT
Morgan Stanley Trims Price Target on Kymera Therapeutics to $37 From $39, Maintains Equalweight Rating	23-08-29	MT
Stifel Raises Kymera Therapeutics' Price Target to $52 From $48, Buy Rating Maintained	23-08-07	MT
Credit Suisse Adjusts Kymera Therapeutics' Price Target to $37 From $36, Keeps Neutral Rating	23-08-04	MT
Truist Initiates Kymera Therapeutics at Buy With $50 Price Target	23-06-30	MT
Morgan Stanley Adjusts Price Target on Kymera Therapeutics to $39 From $41, Maintains Equal-Weight Rating	23-05-09	MT
Raymond James Upgrades Kymera Therapeutics to Outperform From Market Perform, Price Target is $38	23-05-05	MT
Credit Suisse Lowers Kymera Therapeutics' PT to $36 From $39, Notes Lack of Meaningful Catalysts in 2023; Retains Neutral Rating	23-05-05	MT
Credit Suisse Raises Kymera Therapeutics' Price Target to $39 From $32, Keeps Neutral Rating	23-02-24	MT
Wells Fargo Ups Price Target on Kymera Therapeutics to $42 From $40, Maintains Overweight Rating	23-01-03	MT
Stifel Trims Kymera Therapeutics Price Target to $55 From $56, Maintains Buy Rating	22-12-21	MT
Morgan Stanley Adjusts Price Target on Kymera Therapeutics to $41 From $38, Maintains Equalweight Rating	22-12-19	MT
Goldman Sachs Adjusts Price Target on Kymera Therapeutics to $52 From $40, Maintains Buy Rating	22-12-16	MT
SVB Securities Adjusts Price Target on Kymera Therapeutics to $31 From $26, Maintains Market Perform Rating	22-12-15	MT
B. Riley Boosts Price Target on Kymera Therapeutics to $37 From $35, Reiterates Neutral Rating	22-12-15	MT
Stocks Remain Relatively Flat as Investors Wait for Fed Rate-Hike Move	22-12-14	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

33.62 USD

Average target price

51.07 USD

Spread / Average Target

+51.89%

High Price Target

112 USD

Spread / Highest target

+233.14%

Low Price Target

30 USD

Spread / Lowest Target

-10.77%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Kymera Therapeutics, Inc.

Oppenheimer
Truist Securities
Piper Sandler
B. Riley
Wolfe Research
Morgan Stanley
BofA Securities
HC Wainwright
Stifel Nicolaus
Credit Suisse
Raymond James
Wells Fargo Securities
Goldman Sachs
SVB Securities LLC
Jefferies & Co.
Berenberg Bank
JPMorgan Chase
Brookline Capital Management
UBS

Ratings for Kymera Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar